Program
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101
Its studies are mostly in Ovarian Neoplasms, led by Outpace Bio.
Furthest: phase 1, since Jun 12, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Outpace Bio | 10 open or running | phase 1since Jun 12, 2025 | Jun 12, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 12, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07030907 · 3 enrolled · United States
TargetBeta
“A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and conditionally expressing the human cytokine interleukin-2 (IL-2) and containing an epidermal growth f”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07030907Ovarian Neoplasms · United States | 1 | Terminated | Sep 30, 2026 | 3 |
How it is read
Names in the registry
- “OPB-101”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.